Orchestra BioMed Beats EPS Estimates, Misses Revenue

Orchestra BioMed reported a third-quarter adjusted loss of 30 cents per share, better than analysts’ expected 40-cent loss and its 40-cent loss a year earlier. Revenue was about $90,000, below estimates of roughly $131,000 and down from $860,000 a year earlier. The company has beaten consensus earnings-per-share estimates in three of the past four quarters, but topped revenue estimates only once in that period. Its shares traded around $5.73 after the results, while analysts’ ratings were generally positive but included a dissenting sell rating. Investors will be watching management’s outlook and commentary for clues about the company’s earnings trajectory.